Genetic loss of Pd-l1 or immune checkpoint blockade via a monoclonal PD-1–targeting antibody does not ameliorate cystic kidney disease in early- or adult-onset ADPKD. This evidence concerns the gene CD274 and autosomal dominant polycystic kidney disease.